Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-Cross
- Development stage
- Phase 3
- Lead developer
- Sooft Italia
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
I-Cross is a lubricating ophthalmic solution (artificial tear) composed of cross-linked sodium hyaluronate (typically 0.20%). Unlike traditional linear hyaluronic acid, the cross-linked form of hyaluronate in I-Cross offers significantly higher viscoelasticity and mucoadhesiveness, making it more resistant to enzymatic degradation by hyaluronidase. This allows the solution to form a more stable and persistent protective film on the ocular surface, effectively stabilizing the tear film and providing prolonged relief from symptoms of moderate to severe dry eye (keratoconjunctivitis sicca). It is frequently used to manage chronic ocular surface irritation, environmental stress, or post-operative recovery, such as following refractive or cataract surgery.
- Brand names
- I-CrossIcross
- Other names
- Cross-linked sodium hyaluronateCross-linked hyaluronic acidI-Cross 0.2%
02
Targets
CD44 (CD44 antigen)MUC (Mucin family)
Beyond the preview
Go deeper on I-Cross.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I-Cross.